Search
Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial
go.drugbank.com/bio_entities/BE0000176TargetEnzymeHumansFlavoprotein (FP) subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to ubiquinone
Synonyms: Flavoprotein subunit of complex IINADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7
go.drugbank.com/bio_entities/BE0000512TargetHumansAccessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. … Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone
Synonyms: Complex I-B18DTS-201
go.drugbank.com/drugs/DB06071Experimental201 may be suitable for the treatment of many types of solid tumors, including tumors sensitive to doxorubicin and potentially other tumors which are not currently treated with doxorubicin but which express
Olcegepant
go.drugbank.com/drugs/DB04869InvestigationalOlcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine.
Benserazide
go.drugbank.com/drugs/DB12783ApprovedInvestigationalIn particular, although the specific levodopa/benserazide combination is formally approved for use in Canada and much of Europe, the FDA has approved another similar levodopa/dopa decarboxylase inhibitor … Moreover, the European Medcines Agency has conferred an orphan designation upon benseraside since 2015 for its potential to be used as a therapy for beta thalassaemia as well [F3].
Edaravone
go.drugbank.com/drugs/DB12243ApprovedInvestigational[L44017] Edaravone was initially granted orphan designation by the European Medicines Agency on June 19, 2015 [L44007] and was under regulatory review in Europe. … However, the drug manufacturer, Mitsubishi Tanabe Pharma, withdrew the Marketing Authorization Application (MAA) for edaravone from the European market on May 24, 2019, in response to the request made
Empagliflozin
go.drugbank.com/drugs/DB09038ApprovedInvestigationalEmpagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart
Cintredekin besudotox
go.drugbank.com/drugs/DB05305InvestigationalCintredekin besudotox has been developed as a specific tumor-targeting agent, which is administered by positive-pressure convection-enhanced delivery (CED) directly to brain tissue at risk for residual infiltrating glioblastoma multiform...
Small nuclear ribonucleoprotein Sm D2
go.drugbank.com/bio_entities/BE0009119TargetHumansComponent of both the pre-catalytic spliceosome B complex and activated spliceosome C complexes (PubMed:11991638, PubMed:28076346, PubMed:28502770, PubMed:28781166). … Plays a role in pre-mRNA splicing as a core component of the spliceosomal U1, U2, U4 and U5 small nuclear ribonucleoproteins (snRNPs), the building blocks of the spliceosome (PubMed:11991638, PubMed:18984161
Synonyms: snRNP core protein D2Dihydrolipoyl dehydrogenase
go.drugbank.com/bio_entities/BE0002616TargetPseudomonas putidaThe branched-chain alpha-keto dehydrogenase complex catalyzes the overall conversion of alpha-keto acids to acyl-CoA and CO(2).
Synonyms: E3 component of branched-chain alpha-keto acid dehydrogenase complex